ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

AVCT Avacta

43.50
0.25 (0.58%)
Last Updated: 08:16:27
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Avacta LSE:AVCT London Ordinary Share GB00BYYW9G87 ORD 10P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.25 0.58% 43.50 43.00 44.00 43.50 43.25 43.25 65,259 08:16:27
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 23.25M -24.95M -0.0695 -6.22 155.29M
Avacta is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker AVCT. The last closing price for Avacta was 43.25p. Over the last year, Avacta shares have traded in a share price range of 39.75p to 139.00p.

Avacta currently has 359,042,104 shares in issue. The market capitalisation of Avacta is £155.29 million. Avacta has a price to earnings ratio (PE ratio) of -6.22.

Avacta Share Discussion Threads

Showing 80976 to 80996 of 81050 messages
Chat Pages: 3242  3241  3240  3239  3238  3237  3236  3235  3234  3233  3232  3231  Older
DateSubjectAuthorDiscuss
27/11/2024
21:12
King Suarez another multi name poster returns. Canny timing I feel.
amanitaangelicus
27/11/2024
19:07
That was a quick 6 months...
king suarez
27/11/2024
18:18
Except Aman that everything forecast by the loons has happened.

The previous CEO fed out a heap load of BS, Myles assisted ignorant of risks and the extensive due diligence on the history of Ari6000 and 3996.

The lack of efficacy for uprated doses says it all. It’s clearly what Arisaph saw.

Flipped over to the AIM from the US via Avacta and now reality starting to bite.

LFTs a farce, Diagnostics company acquisition up for sale and to go phase 2 would be suicide, but obviously would drag out salaries for longer.

ohwhatfun
27/11/2024
17:13
Ohwhatfun lying merrily away. Board taken over by loons.
amanitaangelicus
27/11/2024
15:24
"See you in 6 months or so".

Thanks. Now f#*CK off then and we'll see you again in the springtime

coley15
27/11/2024
11:24
Time has passed, pointing out the obvious drowned in blinkered hype investor posts.

Arisaph (Yes them) required materially increased efficacy and safety to progress to phase 2. They had seriously wealthy backers/co owner.

Efficacy here, has been woeful less than doxorubicin standard treatment. Clearly Arisaph saw the same and abandoned it. Obviously the method doesn’t work as hoped.

That on top of that chemo interest is backward looking. The pharma industry is chasing new highly efficacious therapies.

Avacta chasing archaic routes with a copycat known failure.

Spikes and drops on private investor surges and abandon ship.

See you in 6 months or so, to see low it is by then.

ohwhatfun
26/11/2024
18:55
If ever there was was comp for spinning a good ole yarn, GLA
repins1
25/11/2024
16:14
50p if your lucky.

Shorts from 74p more attractive?

Lev Sir, would advise stay away, this is another fools gold as with Nov.

cheers

dudishes
25/11/2024
10:04
Very strong nosy buying today . 60p by day end ??
levinson1
22/11/2024
10:45
Q2 2025 Back for a punt? U missed it like the other ditherers.
amanitaangelicus
22/11/2024
09:22
Looking like the quarter selling might have finished.
robers98
22/11/2024
09:09
Yes still around, I like to keep an eye on these lifestyle companies that fail to deliver anything but jam tomorrow stories. Pray tell, when does AVA6000 Phase 2 start? Sometime in 2024 they said, only 5 weeks left now. share price is still on a downward trend with the odd spike around payday loan conversion time. But hey dream on, tomorrow is another day.
1347
22/11/2024
09:08
Stick with me Chesh ...nice little set up play complete. ££££££'s in. My hypothesis on the bent spine ups and downs is better than your glaring zero comment stuff. Funny how you appear again after a fall. Perhaps yourself and Raj might get a room? 2 blatant traders pretending not to be. Funny as.
amanitaangelicus
21/11/2024
22:06
See yur still here 1347. The burk here and I trust you aren't still underwhelmed though it sounds like you could be. Maybe you could meet up with ama for solace as he's fretting over the convi boys.
cheshire pete
21/11/2024
15:13
What's that got to do with Avacta? No-one's going to acquire Avacta out on the strength of one three year Phase 1a trial, all the other pipeline candidates having been quietly dropped, such that they've had to go back to the starting grid with two brand new ones. Hit the snooze button for another few years.
1347
21/11/2024
13:53
Novartis have not finished acquiring and they are today upgrading their numbers again post another acquisition.
viking24
21/11/2024
11:20
POLX FDA Approval received today big rise coming

POLX Polarean Imaging 1.6p I fancy to fill the gap to 3.2p and head to 10p+. Mcap is peanuts and cash position is much longer to Q2 2026 and revenue are higher and growing even more quickly than this.. I see it as a steal for the FDA approved Xenon MRI. No company debt, masssive growth potential in the worlds biggest health market the United States where it's already in 21 clinical settings, best in class next generation MRI. Revenues rising up 3000% to $3mil for 2024 and doubling again next to $6mil in 2025 Cash runway to minimum of Q2 2026, looks set to be extended given revenues ahead of expectations.

Putting this UK recovery play potential on radars as used to trade at 100p and has made significant commercial progress since FDA approval.

Massive takeover target and will be sold for 20p+ share price.

1. September 18th 2024: Interventional radiology vendor Merit Medical to acquire device portfolio for $210M.

APPROX 13P SHARE PRICE EQUIVALENT FOR POLX


2. September 25th 2024: Private equity firm acquiring diagnostic imaging provider for $658M

APPROX 48P SHARE PRICE EQUIVALENT FOR POLX


3. October 14th 2024: Hologic to Acquire Gynesonics The women’s health company will be purchased for approximately $350 million.

APPROX 22P SHARE PRICE EQUIVALENT FOR POLX

4. Bracco current major TR1 Holder of Polarean splashed out $450MILLION for a diagnostic buyout

POLX easy buyout target more massive premiums as per the above imv. DYOR, not advice.

m_night10
21/11/2024
10:17
That Dnt mean anything
letsgo5
21/11/2024
10:07
IPO !US broker is arriving. Peel back on the bench
viking24
21/11/2024
10:03
Looks like you might be right BH. placing at £1 though. :)
rajraj b
21/11/2024
07:41
Another placing is needed very soon , last placing money about to run out
blackhorse23
Chat Pages: 3242  3241  3240  3239  3238  3237  3236  3235  3234  3233  3232  3231  Older

Your Recent History

Delayed Upgrade Clock